New Delhi: Biotechnology major Biocon on Monday said its wholly-owned subsidiary Biocon Biologics has received a positive recommendation from the European Medicines Agency's panel for its breast cancer biosimilar Pertuzumab.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation to the Pertuzumab biosimilar (420 mg concentrate solution for infusion) under the brand name Pebrilzo, the company said in a statement.